NeOnc Technologies Holdings, Inc. - Common Stock (NTHI)

Growing investment in next-generation CNS cancer therapies is driving research into targeted drugs, immunotherapy and new approaches to treating aggressive brain tumors.

EQNX::TICKER_START (NASDAQ:NTHI),(NASDAQ:NBIX),(NASDAQ:ACAD),(NASDAQ:AVXL),(NYSE:MRK) EQNX::TICKER_END

Compassionate care for children in Abu Dhabi, a new research MoU and a senior banking appointment add momentum to NeOnc's development story

Proposed collaboration covers scientific exchange, specialist training and real-world evidence, alongside assessment of clinical trial opportunities and a potential regional presence for NeOnc in Abu Dhabi

Houston, Texas--(Newsfile Corp. - October 16, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) is confronting one of the most consequential...

Treating physicians report that a critically ill three-year-old boy is breathing independently and showing renewed movement following initiation of investigational treatment

With UAE authorizations for both lead drug candidates, NeOnc brings a clinical development perspective to discussions on capital, precision medicine and international collaboration

Appointment strengthens financial governance and supports NeOnc’s clinical development and expansion in Abu Dhabi

November 17 meeting will address Phase 2 study design and potential regulatory pathways

Cash redemption simplifies the capital structure with no common shares issued in the redemption

CEO Amir Heshmatpour has purchased 111,000 shares for approximately $418,700 since the Company announced positive NEO100 Phase 2a results

CALABASAS, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it has entered into definitive securities purchase agreements with new and existing healthcare focused institutional investors for the purchase and sale of 3,571,430 shares of the Company’s common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) and accompanying warrants to purchase up to 3,571,430 shares of the Company’s common stock at a combined purchase price of $4.20 per share (or $4.1999 per pre-funded warrant) and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules. Each pre-funded warrant will be exercisable upon issuance at an exercise price of $0.0001 per share and will expire when exercised in full. Each warrant will be immediately exercisable at an exercise price of $4.20 per share and will expire five years from the date of issuance.

Envoy Medical, Sagtec Global, RHINO Bitcoin and Virtuix Holdings Featured in This Weekend's Global Broadcast

Dallas, Texas--(Newsfile Corp. - August 13, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). Stonegate Capital Partners Updates Coverage on...

Houston, Texas--(Newsfile Corp. - August 12, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) reported encouraging Phase 2a results for intranasal...

Company to request a Type B meeting with the FDA to align on a registrational path in a setting with no approved targeted therapy

Houston, Texas--(Newsfile Corp. - August 11, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) is set up for a potential high...

CALABASAS, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments for central nervous system cancers, today announced financial results for the second quarter ended June 30, 2026, highlighted recent clinical and regulatory progress across its NEO100 and NEO212 programs, and confirmed that topline results from its fully enrolled Phase 2a NEO100 study will be presented on August 12, 2026.

Call to be held Wednesday, August 12, 2026 at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time

Appointment deepens the Board’s strategic and financial oversight as the Company advances its NEO platform toward its next phase of growth

FDA feedback provides detailed manufacturing and formulation requirements for continued late-stage development of NEO212

Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studies

Houston, Texas--(Newsfile Corp. - June 22, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) recently achieved what many biotechnology companies spend...

Clearance enables Phase 2 evaluation of NEO212, the Company’s oral perillyl alcohol-temozolomide conjugate, in the United Arab Emirates

Houston, Texas--(Newsfile Corp. - June 15, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) continues to attract attention within the biotechnology...